Funding Support

Research in the Levings Lab is partially funded by the following grants:

  • Stem Cell Network: A Bioprinted Insulin-Producing Device for Diabetes (2020)
  • CIHR Team Grant - Human Immunology Initiative: Innate and adaptive immune regulation in human type 1 diabetes (2019)
  • US Dept of Defense: Application of CAR-Treg techonology to regulate VCA rejection (2019)
  • NIH: Engineering stem cells for islet cell replacement (2018)
  • Michael Smith Foundation for Health Research: Engineered T regulatory cells to treat Crohn's disease (2018)
  • CIHR: Canadian autoimmunity standardization core (CAN-ASC) (2018)
  • Juvenile Diabetes Research Foundation International (JDRF): Harmonizing biomarkers in clinical trials of ustekinumab (2018)
  • HelmsleyTrust: Engineering antigen-specific regulatory T cells for use in type 1 diabetes (2018)
  • CIHR: Molecular and cellular biology of T regulatory cells (2017)
  • Bristol-Myers Squibb (BMS): Defining Phenotypic and Functional Alterations of Tissue Regulatory T Cells to Assist in the Identification of Novel Targets for Next-generation Therapies in Inflammatory Bowel Disease (2016)
  • Takeda Canada: The Role of CD4+ T cell Subsets in the Mechanism of Action of Vedolizumab in Inflammatory Bowel Disease (2015)